Navigation Links
24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination
Date:3/5/2010

Microbial contamination is the third leading cause of mortality in the U.S., according to the Centers for Disease Control (CDC).

Charleston, SC (PRWEB) March 5, 2010 -- Today’s hospitals have an increasingly dangerous and costly problem. The culprit…Hospital Acquired Infections (HAIs) and they have generated much attention over the last decade. Studies have shown that up to 70% of HAIs are preventable with proper infection control, according to a Nurse Liaison for 24x7 Infection Control, Inc.    

A totally new (to the public) antimicrobial line named Goldshield®™ is a revolutionary product that, through independent studies it was demonstrated to eradicate germs on contact and inhibit their growth. Invented and patented by Emory University, Goldshield®™ is a system of products which includes an antimicrobial that is the first, and only, water-stabilized, non-toxic, non-leaching, environmentally benign solution providing a durable shield against microbial contamination, including mold, mildew and fungi.

Goldshield®™ offers an EPA-registered solution to combat dangerous microbial contamination in virtually every setting including hospitals, outpatient clinics, physicians offices, assisted living facilities, skilled nursing facilities, schools, colleges, athletic clubs, gymnasiums, spas, police departments, emergency medical services, fire departments, correctional institutions, the hospitality industry and commercial laundry facilities, to name a few.

Independent studies conducted at hospitals and universities have demonstrated that Goldshield® is a broad-spectrum bactericide, algaecide and fungicide. In these studies, it has been proven effective against Staphylococcus aureus (Staph), Methicillin-resistant Staphylococcus aureus (MRSA); including HA-MRSA (Healthcare-associated MRSA) and CA-MRSA (community- associated MRSA), Salmonella, E.coli, VRE (Vancomycin-Resistant Enterococci, and other hardy Gram (+) and Gram (-) bacteria. In a recent study in accordance with ASTM (American Society for Testing and Materials) protocols for virucidal efficacy on inanimate surfaces, Goldshield®™ was proven effective against Influenza A as a surrogate for H1N1.

Sharon Harper, an OR nurse and retired, Navy Infection Control Officer, stated, “I have seen the results and can appreciate why Goldshield®™ is so unique. In my opinion, the most exciting use of this new antimicrobial is via a “Bio-Vapor” Steam Cleaning System. This method allows Goldshield®™ to adhere in every ‘nook and cranny’! My mission as the nurse liaison for 24x7 Infection Control, Inc. is to inform government agencies, schools, hospitals, assisted living and long-term care communities that Goldshield®™ is now available.”

The parent company, AP Goldshield LLC is located in the United States, Israel, Asia, and Europe. 24x7 Infection Control, Inc. is an Authorized Distributor for Goldshield®™.

To find out more, please visit www.24x7infectioncontrol.com

Contact:                           
Sharon Harper RN, MSN                                         
LCDR/USN/RET
Sharon (at) 24x7infectioncontrol (dot) com
843-696-6830

###

Read the full story at http://www.prweb.com/releases/NEW/ANTIMICROBIAL/prweb3688064.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
2. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
3. Computers help chemists fight emerging infections
4. Infection contributes to the high rates of oropharyngeal cancers
5. Jefferson immunology researchers halt lethal rabies infection in brain
6. SIV infection of natural hosts provides new insights into HIV disease complexity
7. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
8. Natural aorta grafts have few side effects for infection-prone patients
9. Common misdiagnosis: most women believe they have a yeast infection when they dont
10. Patient Safety Authority Board of Directors Names Infection Advisory Panel
11. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 
(Date:2/11/2016)... Viejo, CA (PRWEB) , ... February 11, 2016 , ... ... Pro X users with customizable backdrops in the Christmas edition of the ProDrop ... of the year. Captivate audiences and invoke the spirit of Christmas using ProDrop's wintry ...
(Date:2/11/2016)... CO. (PRWEB) , ... February 11, 2016 , ... ... people have become more actively engaged in health and wellness best practices in ... importance of riding this trend. February is American Heart Month, which acts as ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting ... Congress (WMIC), will be held in New York City, NY on September 7 ... The congress will highlight and emphasize how imaging reveals a greater understanding of ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... expand dental health services to the developmentally disabled in the Coachella Valley. , ... to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group ... associations of medical professionals throughout the country. The Guard was specifically designed to ... and procedures, employee training, regulatory updates, and compliance coaching. , In addition to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... A Worldwide Clinical Trials expert will ... Victoria Park Plaza in London , 24-25 ... and future advances for late phase research on Wednesday, 24 ... , associate director of project management at Worldwide, will focus ... regulations and standards in late phase research. ...
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... Feb. 10, 2016 Mast Therapeutics, Inc. ... clinical-stage therapies for sickle cell disease and heart failure, ... of 29,090,910 units at a price to the public ... share of the Company,s common stock and one warrant ... at an exercise price of $0.42 per share. The ...
Breaking Medicine Technology: